Tybost
cobicistat
cobicistat
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them,
even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What Tybost is and what it is used for
What you need to know before you take Tybost
How to take Tybost
Possible side effects
How to store Tybost
Contents of the pack and other information
Tybost contains the active substance cobicistat.
Tybost is used for the treatment of human immunodeficiency virus-1 (HIV-1) infection, the virus that causes acquired immune deficiency syndrome (AIDS). It is used in HIV-1 infected adults and adolescents aged 12 years and older:
weighing at least 35 kg (when co-administered with atazanavir 300 mg) or
weighing at least 40 kg (when co-administered with darunavir 800 mg).
Tybost acts as a booster (enhancer) of atazanavir or darunavir (both protease inhibitors) to improve their effect (see section 3 of this leaflet).
St. John’s wort (Hypericum perforatum), a herbal remedy used for depression and anxiety
orally administered midazolam, triazolam, used to help you sleep and/or relieve anxiety
If any of these applies to you, you should not take Tybost and you should tell your doctor immediately.
You must remain under the care of your doctor while taking Tybost.
If any of these applies to you, talk to your doctor before taking Tybost. Children and adolescents
These are mentioned above under the heading “Do not take Tybost-If you are taking medicines containing any one of the following”.
You should not take Tybost with other medicines containing:
Talk to your doctor if you are taking
Tell your doctor if you are taking any of these HIV medicines.
Tell your doctor if you are taking any of these medicines.
Tell your doctor if you are taking these or any other medicines. Do not stop your treatment without contacting your doctor.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Some patients have reported dizziness when Tybost was taken with atazanavir or darunavir. If you are affected while taking Tybost, do not drive and do not use any tools or machines.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
When taking Tybost with atazanavir (300 mg), adolescents must weigh at least 35 kg.
When taking Tybost with darunavir (800 mg), adolescents must weigh at least 40 kg.
If you accidentally take more than the recommended dose of Tybost you may be at increased risk of experiencing side effects with this medicine (see section 4 of this leaflet).
Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.
It is important not to miss a dose of Tybost. If you do miss a dose and notice:
Wait and take the next dose, with food, at your usual time.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. When treating HIV infection, it is not always possible to tell whether some of the unwanted effects are caused by Tybost or by other medicines that you are taking at the same time, or by the HIV disease itself. The following side effects may occur when taking Tybost with atazanavir.
(may affect more than 1 in 10 people)
feeling sick (nausea)
yellowing of the skin and/or eyes (jaundice)
(may affect up to 1 in 10 people)
high sugar levels in the blood (hyperglycaemia)
increased appetite, disturbed sense of taste, dry mouth
headache, dizziness
vomiting, diarrhoea, stomach pain, problems with digestion resulting in pain after meals (dyspepsia), feeling bloated, wind (flatulence)
increased levels of bilirubin in the blood (hyperbilirubinaemia)
rash
difficulty sleeping, abnormal dreams, drowsiness, tiredness (fatigue)
(may affect up to 1 in 100 people)
blood in the urine (haematuria)
protein in the urine (proteinuria)
feeling depressed
itchiness
aching muscles, weakness
kidney stones
fever
sleep disorder
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
For more information on the side effects of atazanavir or darunavir see the package leaflets for these medicines.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Tablet core
Croscarmellose sodium, magnesium stearate, microcrystalline cellulose (E460), silicon dioxide (E551).
Film-coating
Sunset yellow FCF aluminium lake (E110), macrogol 3350 (E1521), polyvinyl alcohol (partially hydrolysed) (E1203), talc (E553b), titanium dioxide (E171), iron oxide yellow (E172) (see section 2 of this leaflet).
Tybost film-coated tablets are orange, round, biconvex tablets, debossed on one side with “GSI” and plain-faced on the other side of the tablet.
Tybost comes in bottles of 30 tablets (with a silica gel sachet or canister that must be kept in the bottle to help protect your tablets). The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.
County Cork, T45 DP77
Ireland
Gilead Sciences Ireland UC
IDA Business & Technology Park Carrigtohill
County Cork
Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Gilead Sciences Belgium SPRL-BVBA Tél/Tel: + 32 (0) 24 01 35 50
Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702
Gilead Sciences Ireland UC
Тел.: + 353 (0) 1 686 1888
Gilead Sciences Belgium SPRL-BVBA Tél/Tel: + 32 (0) 24 01 35 50
Gilead Sciences Ireland UC
Tel.: + 353 (0) 1 686 1888
Gilead Sciences Sweden AB
Tlf: + 46 (0) 8 5057 1849
Gilead Sciences Ireland UC
Tel: + 353 (0) 1 686 1888
Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0
Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98
Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702
Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849
Gilead Sciences Ελλάς Μ.ΕΠΕ. Τηλ: + 30 210 8930 100
Gilead Sciences GesmbH Tel: + 43 1 260 830
Gilead Sciences, S.L.
Tel: + 34 91 378 98 30
Gilead Sciences Poland Sp. z o.o.
Tel.: + 48 22 262 8702
Gilead Sciences
Tél: + 33 (0) 1 46 09 41 00
Gilead Sciences, Lda.
Tel: + 351 21 7928790
Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888
Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888
Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 999
Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888
Gilead Sciences Sweden AB Sími: + 46 (0) 8 5057 1849
Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 210
Gilead Sciences S.r.l. Tel: + 39 02 439201
Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849
Gilead Sciences Ελλάς Μ.ΕΠΕ. Τηλ: + 30 210 8930 100
Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849
Gilead Sciences Poland Sp. z o.o.
Tel: + 48 22 262 8702
Gilead Sciences Ireland UC
Tel: + 44 (0) 8000 113 700